Seres grabs $20M on PhI­II mi­cro­bio­me launch

Seres $MCRB is tak­ing an­oth­er step for­ward in its come­back ef­fort on a mi­cro­bio­me drug that rat­tled every­one in the field when it failed a mid-stage study. The biotech says that it has learned from its set­back and has now start­ed a study for pa­tients with mul­ti­ple re­cur­rent C. dif­fi­cile in­fec­tion that it’s hop­ing will serve as the piv­otal Phase III for SER-109. That move — the most ad­vanced mi­cro­bio­me study in the gut re­search world — was worth a $20 mil­lion mile­stone pay­ment from its part­ners at Nestlé Health Sci­ence.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN